At a glance
- Originator Merck & Co
- Class Anti-ischaemics; Antihyperlipidaemics
- Mechanism of Action Cholesterol inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 06 Jul 1995 Discontinued-II for Atherosclerosis in Germany (Unknown route)
- 06 Jul 1995 Discontinued-Preclinical for Atherosclerosis in Italy (Unknown route)
- 19 May 1995 Discontinued-II for Hyperlipidaemia in Germany (Unknown route)